Aeterna Zentaris’ endometrial cancer drug fails in Phase III

3rd May 2017 Uncategorised 0

A late stage clinical study of Aeterna Zentaris’ Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer has failed to meet its primary endpoint of demonstrating a statistically significant increase in survival in patients taking the drug.

More: Aeterna Zentaris’ endometrial cancer drug fails in Phase III
Source: News